Search

Your search keyword '"Baeten, Jared M."' showing total 142 results
Start Over Author "Baeten, Jared M." Journal jaids: journal of acquired immune deficiency syndromes
142 results on '"Baeten, Jared M."'

1. Intimate Partner Violence and Adherence to PrEP and ART Among Ugandan HIV Serodifferent Couples.

Author

Thomas, Dorothy, Nakabugo, Lylianne, Nambi, Florence, Kibuuka, Joseph, Muwonge, Timothy R., Feutz, Erika, Thomas, Katherine K., Simoni, Jane M., Montgomery, Elizabeth T., Ware, Norma, Wyatt, Monique A., Katz, Ingrid T., Kadama, Herbert, Mujugira, Andrew, Heffron, Renee, Baeten, Jared M., Donnell, Deborah, Barnabas, Ruanne, Grabow, Cole, and Meisner, Allison

Published
2024
Full Text
View/download PDF

6. High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study.

Author

Beesham, Ivana, Parikh, Urvi M., Mellors, John W., Joseph Davey, Dvora L., Heffron, Renee, Palanee-Phillips, Thesla, Bosman, Shannon L., Beksinska, Mags, Smit, Jennifer, Ahmed, Khatija, Makkan, Heeran, Selepe, Pearl, Louw, Cheryl, Kotze, Philip, Hofmeyr, G. Justus, Singata‐Madliki, Mandisa, Rees, Helen, Baeten, Jared M., and Wallis, Carole

Published
2022
Full Text
View/download PDF

16. Age-Specific Risk Scores Do Not Improve HIV-1 Prediction Among Women in South Africa.

Author

Peebles, Kathryn, Palanee-Phillips, Thesla, Balkus, Jennifer E., Beesham, Ivana, Makkan, Heeran, Deese, Jennifer, Smit, Jennifer, Heffron, Renee, Morrison, Charles S., Philip, Neena M., Malahleha, Mookho, Kasaro, Margaret, Yuthika Naidoo, Nielson, Tanya, Reddy, Krishnaveni, Kotze, Philip, Ahmed, Khatija, Rees, Helen, Baeten, Jared M., and Barnabas, Ruanne V.

Published
2020
Full Text
View/download PDF

23. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.

Author

Makanani, Bonus MBBS, FCOG, Balkus, Jennifer E. PhD, MPH, Jiao, Yuqing MS, Noguchi, Lisa M. CNM, PhD, Palanee-Phillips, Thesla PhD, Mbilizi, Yamikani MBBS, Moodley, Jothi BS, Kintu, Kenneth MBChB, Reddy, Krishnaveni MBChB, Kabwigu, Samuel MBChB, Jeenariain, Nitesha MBChB, Harkoo, Ishana MBChB, Mgodi, Nyaradzo MBChC, Mmed, Piper, Jeanna MD, Rees, Helen MD, MS, Scheckter, Rachel MPH, Beigi, Richard MD, and Baeten, Jared M. MD, PhD

Published
2018
Full Text
View/download PDF

25. Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa.

Author

Velloza, Jennifer, Baeten, Jared M., Haberer, Jessica, Ngure, Kenneth, Irungu, Elizabeth, Mugo, Nelly R., Celum, Connie, and Heffron, Renee

Abstract

Background: Low adherence can undermine the efficacy of daily oral pre-exposure prophylaxis (PrEP). Mental health conditions, particularly depression, could be associated with low PrEP adherence, especially for women. Setting: We analyzed data from 1013 Kenyan and Ugandan HIV-uninfected participants in the Partners Demonstration Project, an open-label study of PrEP delivered to HIV-uninfected members of serodiscordant couples. Methods: Participants completed quarterly visits over 2 years and were encouraged to use PrEP until their partners living with HIV had ≥6 months of antiretroviral therapy use (when viral suppression was expected). PrEP adherence was measured daily with electronic medication event monitoring system caps and dichotomized into low (<80% of expected bottle openings) and high adherence. Depression was assessed annually using the 16-item Hopkins Symptom Checklist screening tool; scores >1.75 indicate "probable depression." The association between probable depression and PrEP adherence was assessed separately for men and women using generalized estimating equations and marginal structural models. Results: At enrollment, 39 (11.7% of 334) women and 64 (9.4% of 679) men reported symptoms indicating probable depression, and these proportions decreased during follow-up (P < 0.001 for women and men). Probable depression was significantly associated with low PrEP adherence among women (adjusted risk ratio = 1.77; 95% confidence interval: 1.14 to 2.77; P = 0.01); there was no association between depression and adherence among men (P = 0.50). Marginal structural models and sensitivity analyses confirmed these findings. Conclusions: Depression was relatively uncommon in this population and was an independent risk factor for low PrEP adherence among women. For PrEP programs targeting African women, integration of depression screening may improve PrEP effectiveness. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

27. Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.

Author

Mugwanya, Kenneth K., Baeten, Jared M., Wyatt, Christina, Mugo, Nelly R., Celum, Connie L., Ronald, Allan, Kiarie, John, Katabira, Elly, and Heffron, Renee

Abstract

Background: Wide-scale implementation of oral tenofovir-based pre-exposure prophylaxis (PrEP) for HIV prevention is now policy in many settings. However, the optimal frequency for monitoring kidney function remains uncertain. We investigated the impact of 6-monthly compared to 3-monthly creatinine clearance (CrCl) monitoring on the identification of moderate kidney dysfunction, defined as CrCl <60 mL/min. Methods: Data were from two prospective daily oral PrEP studies in Kenya and Uganda: the Partners PrEP Study, a randomized safety and efficacy trial of PrEP that conducted 3-monthly CrCl monitoring (n=4404) and the Partners Demonstration Project (n=954), an open-label delivery study of PrEP that used 6-monthly monitoring. CrCl =60 mL/min was required for enrollment in both studies. Abnormal results were followed with confirmatory testing within approximately 1 week. Follow-up was for up to 24 months. Results: Of 5358 participants included in the analysis, 87% were <45 years, a third were female, and 21% had a baseline CrCl between 60-90 mL/min. Confirmed CrCl <60 mL/min events were rare, occurring in 52 individuals (<1%) in 24-months. The 12-month cumulative proportion of persons with CrCl <60 mL/min was 0.2% with 3-monthly screening and 0.5% with 6-monthly screening. Older age (>45 years), lower weight (<55 kg), elevated blood pressure (>140 mm/Hg), and baseline CrCl between 60-90 mL/min were independently associated with CrCl decline <60 mL/min during follow up. Conclusions: In these two PrEP studies, with a generally young participants, the occurrence and pattern of clinically relevant decline in CrCl were not qualitatively different based on 3- or 6-monthly CrCl monitoring schedule. These data suggest that for most persons receiving PrEP for up to 24 months, less frequent CrCl monitoring would be safe and reduce required expenditures for. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

35. Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data.

Author

Patel, Rena C., Baeten, Jared M., Heffron, Renee, Ting Hong, Davis, Nicole L., Nanda, Kavita, Coombs, Robert W., Lingappa, Jairam R., Bukusi, Elizabeth A., Hurst, Stacey, Thomas, Katherine K., Kourtis, Athena P., and Mugo, Nelly

Abstract

Background: To explore the association between concomitant hormonal contraceptive and antiretroviral therapy (ART) use and (1) plasma viral suppression and (2) genital HIV shedding among HIV-positive women initiating ART. Methods: We analyzed plasma viral load and genital viral RNA shedding from 1079 HIV-positive women initiating ART who were followed prospectively in 3 sub-Saharan African HIV prevention studies. Plasma and endocervical swab samples were collected every 6 months. Self-reported contraceptive use was categorized into injectable, implant, oral, or nonhormonal/no contraception. We used multivariate Cox regression to assess time to plasma viral suppression and logistic regression with generalized estimating equations to assess genital viral shedding for each contraceptive method. Results: At the time of ART initiation, there were 211 (20%) injectable, 69 (6%) implant, 50 (5%) oral, and 749 (69%) nonhormonal or no method users. Plasma viral suppression was high (90% by 6 months) and hormonal contraceptives did not diminish time to plasma viral suppression as compared to nonhormonal/no methods [adjusted hazard ratios: injectables 0.89 (95% confidence interval: 0.75 to 1.07), implants 0.91 (0.68 to 1.23), and oral methods 1.33 (1.06 to 1.66)]. Genital viral shedding was uncommon any time after ART initiation (only 9% of samples had detectable viral shedding) and hormonal contraceptives were not associated with an increased detection of genital viral shedding [adjusted odds ratios: injectables 1.07 (0.69 to 1.65), implants 0.67 (0.31 to 1.49), and oral methods 0.56 (0.19 to 1.69)]. Conclusions: The hormonal contraceptives assessed were not associated with reduced ART effectiveness among HIV-positive women initiating ART. HIV-positive women should continue to be offered contraceptive options, including hormonal ones that best meet their needs. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

42. Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.

Author

Pattacini, Laura, Baeten, Jared M., Thomas, Katherine K., Fluharty, Tayler R., Murnane, Pamela M., Donnell, Deborah, Bukusi, Elizabeth, Ronald, Allan, Mugo, Nelly, Lingappa, Jairam R., Celum, Connie, McElrath, M. Juliana, and Lund, Jennifer M.

Abstract

Objective: Two distinct hypotheses have been proposed for T-cell involvement in protection from HIV-1 acquisition. First, HIV-1--specific memory T-cell responses generated on HIV-1 exposure could mount an efficient response to HIV-1 and inhibit the establishment of an infection. Second, a lower level of immune activation could reduce the numbers of activated, HIV-1--susceptible CD4+ T cells, thereby diminishing the likelihood of infection. Methods: To test these hypotheses, we conducted a prospective study among high-risk heterosexual men and women, and tested peripheral blood samples from individuals who subsequently acquired HIV-1 during follow-up (cases) and from a subset of those who remained HIV-1 uninfected (controls). Results: We found no difference in HIV-1--specific immune responses between cases and controls, but Treg frequency was higher in controls as compared with cases and was negatively associated with frequency of effector memory CD4+ T cells. Conclusions: Our findings support the hypothesis that low immune activation assists in protection from HIV-1 infection. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

47. An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda.

Author

Psaros, Christina, Haberer, Jessica E., Katabira, Elly, Ronald, Allan, Tumwesigye, Elioda, Campbell, James D., Wangisi, Jonathan, Mugwanya, Kenneth, Kintu, Alex, Enyakoit, Michael, Thomas, Katherine K., Donnell, Deborah, Krows, Meighan, Kidoguchi, Lara, Ware, Norma, Baeten, Jared M., Celum, Connie, Bangsberg, David R., and Safren, Steve A.

Published
2014
Full Text
View/download PDF

49. HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention.

Author

Donnell, Deborah, Baeten, Jared M., Bumpus, Namandjé N., Brantley, Justin, Bangsberg, David R., Haberer, Jessica E., Mujugira, Andrew, Mugo, Nelly, Ndase, Patrick, Hendrix, Craig, and Celum, Connie

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) is a novel HIV prevention strategy for which adherence is a known determinant of efficacy. Blood concentrations of PrEP medications are one objective marker of adherence.In a placebo-controlled PrEP efficacy trial of tenofovir disoproxil fumarate (TDF) and TDF with emtricitabine (FTC/TDF) among 4747 African women and men with an HIV-infected partner, we measured plasma tenofovir concentrations from participants in the active PrEP arms: 29 HIV seroconverters (cases) and 196 randomly selected controls who remained uninfected.Among controls, 71% of visits had tenofovir concentrations >40 ng/mL, consistent with steady-state daily dosing, compared with 21% of cases at the visit HIV was first detected. Pill count data indicated that 96% of controls and 66% of cases had >80% adherence for these same visits. The estimated protective effect of PrEP against HIV, based on concentrations >40 ng/mL, was 88% (95% confidence interval: 60 to 96, P < 0.001) for individuals receiving TDF and 91% (95% confidence interval: 47 to 98, P = 0.008) for individuals receiving FTC/TDF. Controls had consistent patterns of PrEP concentrations during follow-up; among the 81% with concentrations >40 ng/mL at month 1, 75% maintained this concentration at month 12. Only 5 of 29 seroconverters seemed to be consistently adherent to PrEP. Tenofovir concentrations >40 ng/mL were associated with older age and shorter time on study; concentrations 40 ng/mL occurred more commonly when participants reported no sex with their HIV-infected partner.Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition. Most of those who took PrEP seemed to have high and consistent adherence. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results